and hope Thank everyone be is good I David, afternoon, everyone. to you, healthy and safe. continues
$XX.X comparable revenue XXXX well issuing the With the reported million. preannouncement, million quarter in of third the year. strong a recovery full than guidance to $XX.X reported underway, the to $XX are third revenue which pandemic our second total $XX As we we sales the of comfortable to for is October year more in guided XXXX quarter double was from in this and million, quarter million the
levels, we industry. While believe we actually our than faster global back we are recovering our XXXX revenue now to are
aesthetic levels attributed is of patients and doctors. of only amplified to to returning continued in but both superior how be we also our can actually have the not share communicate our how gains, implants, efforts Our which success indicative safety at pre-pandemic digital market and profile
strong cash to expenses on addition operating led and decrease our burn. this our focus In quarter, to line a driving in lowering top continued efficiencies sales
quarter, at our a share us continue the XX million. million, These of During $X affords us to giving for strong and and the us burn market our cash cash financial was managing continued growth September third keeps business in a position position flexibility gains. $XX.X
and track. Equally our returned Importantly, enter are on the to our U.S. have and to world, technologies a of towards yet on our in growth we XXXX. approval doing the in submission market time pipeline line normal, gain but business industry most to sales path remains so. we continue the Like advance important, clear in not contribute will R&D quarter, our to the that regulatory
Of in places, are sales this as XX to country-to-country but manage stability course, us given we period. seeing in business throughout some volatility our COVID-XX some countries flare than up has more
but majority surgeons. the other even controlled of As not owned It generally breast performed where of surgeons restrictions helps or in government have by procedures that clinics, plastic certainly in which limited today, operating plastic enhancement are private activities. are hospitals are
operate are levels, countries at performing procedures. countries all in and we all not procedures performing While pre-pandemic which open are
quarter. into this quarter importantly, Brazil. or have fully April, lows the have October finished Our Most of has things Asia seen in region, of last to above Latin worst levels were since at with continuing the QX fourth sales appears the continued Europe in month-over-month we improvements third including seen America reported improvement the year. and reopened continued the and across and
which from sales using in except to were procedures. for important many quarter levels shutdowns. direct of geographies, Third our indicator busier XXXX, back to the indicator never their quarter third patients strong. as are by sales, from March unaffected X as of than The first is aesthetic interested home sales, to continue Across takeaway best hear have COVID our which that the Patient time real-time surgeons are of recover final trends, Distributor were results be gains demand sequential viewed the this: they an and been direct at weeks work we is direct of stronger which from quarter they showed of reliable demand, mostly most the sales. most consistently new backlogs that through in this future
increased plastic of surgeons in more the time the that have pandemic and at and education the consultations. unexpected are is initial interesting with of to online adept patients become comfortable tools patients and outcomes home, with eager invest for One and Both themselves. much
noted our we surgeon level last outlook of As positive. optimism and quarter, plastic business the quite remains customers among
key ago. highlight data numbers of data compelling. recap remained Turning sets the data to our represent of approximately at of implant a below weeks market know purchasing XX-year like historical some to to safety If X%. years. breast at the events. would past rupture. along every data recent let the industry our how report With beyond rate complication, the a safety perceive support At speaks particular, an and extended less incentivized of us procedures. our the over to doctors pleased all one we findings, success event, re-operations. in the women end like and our grow we the reported device-related these number This we could important studies incredibly of the coverage, points post-market sources, continued with total procedures warranty competitive the in Of economically than only I general. X% X are when to Symposium for that metrics of X that augmentation women unmatched about of some most to of I widely were few perception symposium, variety the safety addressable of from XX-year If data Motiva surveillance substantially. will would could These breast new complication improvement capsular are evaluating contracture and from dramatic It data announced discussed however. improves, them, required the data, yet something X.XX%, warranty a XX,XXX Patients industry. published advantage, of change just safety This for it X augmentation coverage reported demonstrating is a
heart patient performance results focus profile, of forums and we like on safety of data generating are Word-of-mouth our is are online superior And the regarding our an success. is products experiences. improved our important to While and more would that we the even improved the important component our of growth. at
behind implants with and experiences nearly force second Their results part products. technological Motiva As of X.X clinical plastic experiences million implants worldwide the match shared our last the are panel Motiva business, discuss between driving been real-world Motiva over in leading a and who belief the our the symposium this our the differences XX why and other supporting important are surgeons the placed featured body growing evidence have firsthand of of years.
Surgeons it If you I symposium, find a you the listen to peers. did our do archived not their to to get time hope chance taking on time are so. catch we And website. to have
offers both interested existing MotivaEdge latest breast online new digital in and the surgeons education platform in of and training implant innovations and and Our seminars programs attract technology.
than audience other this MotivaEdge professionals. online XX,XXX scientific plastic with more for has So been surgeons and far medical total events the year,
pipeline. our on update an for Now product
have technologies, with growth exciting which We drivers of expander. of several represent in and Beginning a Flora Motiva number innovative tissue new XXXX. potential our
by next our service. early commercial year. We We its very advance with market ease RFID are port our launch far, including reporting of in sites Flora, the integrated in continuing Europe advancements commenting on the in used receptive proprietary of In so to that offered use satisfaction collect broad early will overall SmoothSilk a comfort. and be X flora patient has the experience surgeons believe feedback bioengineered and to been encouraging patients have
already are means breast market. to the reconstruction procedures this in we expanders be to pair will that available access implants Motiva in our the ability one of important them Europe, fully advanced tissue Although with able most used
to to XXX(k) the $XXX global for the portion our submit now U.S., cleared first in in able tissue half As of by FDA, the the XXXX. of million be access Flora market. expect expander Once will the we largest we
offering mechanical markets, enhanced Asia of features including The most in premium and properties, receipt advanced in many in satisfaction. successful ergonomics, should including and the improved mark quarter. of for our Europe our Europe ErgonomixX Pacific. builds even become CE this implant ErgonomixX patient product, Motiva greater new expect best-selling and result upon has in fourth a Ergonomix chemistry innovative We implant, which
of range we be throughout ErgonomixX, to so to is feature-rich, over with available switch Ergonomix it price Plastic familiar to As premium Ergonomix. command will a Europe. which ErgonomixX a should in be wide able surgeons easily expect sizes
Mia, breast Turning augmentation invasive to program. Motiva our minimally
we to fine-tune as surgical the make We are continuing good technique. progress
Thailand. are series the creating end experience IRB opportunity America quarter, we to promising series the new aesthetics Mia During by breast in initiate Latin is a we for the excited market are of by we a the To and product patient year. technology, approval the very broaden begin expand Motiva addressable category. by received our patient even planning to a to also in further, a
meaningfully are is Motiva around the portfolio is similar If would and of Motiva procedure to in breast our interested of number to be our outcomes already and safety surgeons many product world, innovative current choice confident less who differentiate the and the introduce implant we our market. markets. large Mia to Chinese would it We a large the U.S. aesthetic in further for the invasive contribute women with and are eager of growth implants. successful, us to
in with We approval surgeon approval this to are to information, date, Approximately remain even product breast challenging first very X-year scheduling we on world, strong for plastic as in to of The pandemic expect environment. Study activities half users the our clinical of for requirements. during discussed. implant study-related submission are trial, the are U.S. digital follow-up our in progress this active previously capabilities. States is plastic of to in this the and reached geography. IDE continuing XXXX, aesthetic education all FDA patients Customers for compliance breast high China, of regulatory visits largest their women are our Motiva half all United and track consultations, market offer the continuing and and and single more and and patients surgeons continuing pursue the digital during we cohorts the well market to enhancement plays represents follow-up anniversary have in make
demonstrate very are Motiva an to eager We the FDA and clinical trial. of advantages
Renee to successfully still progress. was financials the we are and delayed discuss steady call to You like second by Renee? enrollment to completed that, continues, making quarter. in reconstruction cohorts, epidemic, the in reconstruction Enrollment turn our I'd the recall revision over we remaining sub-cohort detail. will the which in during the With
